tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Editas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
The FlyEditas Medicine reports new in vivo data on HBG1/2 promoter editing in HSCs
4h ago
EDIT
Editas Medicine Unveils Promising Gene Editing Data
PremiumCompany Announcements
Editas Medicine Unveils Promising Gene Editing Data
4h ago
8K
EDIT
Editas Medicine Unveils In Vivo Gene Editing Data
PremiumCompany Announcements
Editas Medicine Unveils In Vivo Gene Editing Data
1d ago
8K
EDIT
Editas Medicine reports new in vivo proof of concept data for liver target
PremiumThe Fly
Editas Medicine reports new in vivo proof of concept data for liver target
1d ago
EDIT
Editas Medicine price target lowered to $4 from $8 at Baird
PremiumThe Fly
Editas Medicine price target lowered to $4 from $8 at Baird
1d ago
EDIT
Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
PremiumRatingsEditas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
1d ago
EDIT
Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
Premium
Ratings
Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
2d ago
EDIT
Editas Medicine reports Q1 EPS (92c), consensus (59c)
Premium
The Fly
Editas Medicine reports Q1 EPS (92c), consensus (59c)
2d ago
EDIT
Editas Medicine expects cash to fund operations into Q2 of 2027
PremiumThe Fly
Editas Medicine expects cash to fund operations into Q2 of 2027
2d ago
EDIT
Editas says U.S. Court of Appeals remands CRISPR patent interference decision
PremiumThe Fly
Editas says U.S. Court of Appeals remands CRISPR patent interference decision
2d ago
EDIT
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
2d ago
FTI
SAP
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
5d ago
DNA
AZUL
Editas Medicine initiated with a Buy at H.C. Wainwright
PremiumThe FlyEditas Medicine initiated with a Buy at H.C. Wainwright
16d ago
EDIT
Is EDIT a Buy, Before Earnings?
Premium
Pre-Earnings
Is EDIT a Buy, Before Earnings?
16d ago
EDIT
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
19d ago
DDC
PLX
Editas Medicine Announces CFO Transition
PremiumCompany Announcements
Editas Medicine Announces CFO Transition
2M ago
8K
EDIT
Dyne Therapeutics appoints Erick Lucera as CFO
PremiumThe Fly
Dyne Therapeutics appoints Erick Lucera as CFO
2M ago
DYN
EDIT
Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed
PremiumThe Fly
Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed
2M ago
EDIT
Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
PremiumRatings
Cautious Hold Rating on Editas Medicine Amid Early Development Stage and Long-Term Milestones
2M ago
EDIT
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
2M ago
ACIU
ADMA
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
Premium
Ratings
Sell Rating for Editas Medicine Amid Strategic Shift and Competitive Pressures
2M ago
EDIT
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
Premium
Ratings
Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position
2M ago
EDIT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >